Sanofi Consumer Healthcare India Q1 results PAT up 12.9%
Mumbai: Sanofi Consumer Healthcare India Ltd. has announced the company's Q1 results with Profit After Tax (PAT) at Rs 500 million, which stands 12.9% above last quarter of Q4 2024.
With an increase of Rs 2.4 per share, landing the EPS at Rs 21.7. The Company reported revenue from operations of Rs 1726 million.
Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, “We continue to focus on strengthening our operations and continues to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.”
The Q1 2025 also witnessed a successful launch of Allegra D, an addition to the existing portfolio of Allegra variants in India; a brand with over 25 years legacy in India.
Q1 2025 and Q1 2024 are not directly comparable, due to demerger and voluntary product recall of certain variants of key brands.
Sanofi Consumer Healthcare India has emerged as a distinct legal entity following its demerger from Sanofi India Limited. This demerger, executed under the Scheme of Arrangement, was sanctioned by the Mumbai bench of the National Company Law Tribunal and became effective on 1st June 2024. In alignment with Sanofi's global strategy, Sanofi Consumer Healthcare India is now operating independently, with a dedicated focus on the Consumer Healthcare sector.
Sanofi Consumer Healthcare India Limited has portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care, and Multivitamins and Herbal/Traditional Dietary Supplements. Its key brands include Allegra, DePURA, Avil, and Combiflam.
Next Story